Alnylam Pharmaceuticals (ALNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2017 | 12-2016 | 09-2016 | 06-2016 | 03-2016 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 171,079 | 193,617 | 168,481 | 271,076 | 231,278 |
| Marketable Securities | 388,525 | 433,182 | 544,655 | 585,326 | 782,356 |
| Receivables | 19,457 | 23,334 | 15,146 | 9,514 | 8,814 |
| TOTAL | $597,188 | $671,877 | $747,564 | $888,068 | $1,050,074 |
| Non-Current Assets | |||||
| PPE Net | 129,962 | 114,572 | 74,219 | 55,394 | 36,814 |
| Investments And Advances | 405,305 | 474,799 | 489,566 | 437,229 | 228,590 |
| Other Non-Current Assets | 1,471 | 1,562 | 1,561 | 1,471 | 1,471 |
| TOTAL | $536,738 | $590,933 | $565,346 | $494,094 | $266,875 |
| Total Assets | $1,133,926 | $1,262,810 | $1,312,910 | $1,382,162 | $1,316,949 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 25,371 | 54,465 | 23,137 | 12,824 | 17,442 |
| Accrued Expenses | 31,842 | 42,118 | 36,211 | 37,551 | 30,805 |
| TOTAL | $95,786 | $131,699 | $81,761 | $70,575 | $66,369 |
| Non-Current Liabilities | |||||
| Long Term Debt | 150,000 | 150,000 | 150,000 | 150,000 | N/A |
| Deferred Revenues | 38,573 | 35,116 | 22,413 | 20,200 | 18,122 |
| Other Non-Current Liabilities | 3,184 | 3,067 | 1,991 | 1,777 | 1,373 |
| TOTAL | $207,239 | $210,890 | $216,181 | $213,105 | $61,529 |
| Total Liabilities | $303,025 | $342,589 | $297,942 | $283,680 | $127,898 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 86,190 | 86,014 | 85,814 | 85,725 | 85,561 |
| Common Shares | 861 | 859 | 858 | 856 | 855 |
| Retained earnings | -1,764,101 | -1,656,811 | -1,543,877 | -1,439,806 | -1,349,677 |
| Other shareholders' equity | -33,828 | -33,441 | -27,778 | -28,296 | -9,011 |
| TOTAL | $830,901 | $920,221 | $1,014,968 | $1,098,482 | $1,189,051 |
| Total Liabilities And Equity | $1,133,926 | $1,262,810 | $1,312,910 | $1,382,162 | $1,316,949 |